Zacks Investment Research lowered shares of Koninklijke DSM (NASDAQ:RDSMY) from a buy rating to a sell rating in a research report released on Tuesday morning.

According to Zacks, “DSM N V ADR is involved in the Chemicals Industry. Their main focus is on base materials, performance materials, materials processing, base chemicals and fine chemicals and coating resins. They are also involved in the exploration and development of oil and natural gas deposits in the North Sea, as well as the licensing of chemical technology and know-how; in addition the company produces ingredients for bakery products. DSM is a world market leader in a number of products, including caprolactam, melamine and EPDM synthetic rubber. “

Separately, HSBC Holdings plc began coverage on shares of Koninklijke DSM in a report on Friday, September 1st. They issued a buy rating on the stock.

Koninklijke DSM (NASDAQ RDSMY) traded up $0.12 on Tuesday, reaching $22.18. 39,902 shares of the company’s stock were exchanged, compared to its average volume of 35,008. Koninklijke DSM has a 1 year low of $14.50 and a 1 year high of $22.29.

ILLEGAL ACTIVITY WARNING: “Koninklijke DSM (RDSMY) Downgraded by Zacks Investment Research” was first posted by Watch List News and is owned by of Watch List News. If you are reading this news story on another domain, it was stolen and reposted in violation of US & international trademark & copyright law. The original version of this news story can be accessed at

About Koninklijke DSM

Koninklijke DSM N.V. (Royal DSM) is a global science-based company, engaged in offering health, nutrition and materials. The Company’s segments include Nutrition, Performance Materials, Innovation Center and Corporate Activities. Its Nutrition segment includes DSM Nutritional Products and DSM Food Specialties.

Get a free copy of the Zacks research report on Koninklijke DSM (RDSMY)

For more information about research offerings from Zacks Investment Research, visit

Receive News & Ratings for Koninklijke DSM Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Koninklijke DSM and related companies with Analyst Ratings Network's FREE daily email newsletter.